

Bioresorbable Scaffolds: Market Research Report

<https://marketpublishers.com/r/BF8B659E49BEN.html>

Date: April 2018

Pages: 126

Price: US\$ 5,450.00 (Single User License)

ID: BF8B659E49BEN

Abstracts

This report analyzes the worldwide markets for Bioresorbable Scaffolds in US\$ Thousand.

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -

Abbott Laboratories

Amaranth Medical, Inc.

Arterial Remodeling Technologies SA

BIOTRONIK SE & Co. KG

Elixir Medical Corp.

Kyoto Medical Planning Co., Ltd.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

BioResorbable Scaffolds/Stents – A Prelude
Clinical Characteristics of Various Coronary Stents
Bioresorbable Vascular Scaffolds: Advantages and Challenges
Evolution of Coronary Stents
Global Coronary Stents Market – A Few Key Facts
Bioresorbable Stents – A Revolutionary Technology, Riddled with Controversies
Abbott Stops Sales of the Once Promising ‘Absorb’ Bioresorbable Stents due to Adverse Events
Impact of Abbott’s Withdrawal of Absorb on the Bioresorbable Stent Industry
Challenges in Next-generation BVS Development
Other Available Bioresorbable Scaffolds Exhibit Potential
Approved Bioresorbable Scaffolds
Magmaris Exhibits Stability and Safety with Lack of Scaffold Thrombosis Occurrence
Fantom from REVA Medical
DESolve from Elixir Medical
ART from Arterial Remodeling Technologies
Bioresorbable Scaffolds in Pipeline
Current & Future Analysis
Developing Countries – Hot Spots for Growth

2. ABSORB III TRIALS - CHANGING THE FACE OF THE BIORESORBABLE STENTS INDUSTRY

Absorb Bioresorbable Scaffold/Stent Trials – Adverse Outcomes after Two Years of Placement
The ABSORB III Trials
Performance of Absorb in Smaller Vessels

3. GROWTH DRIVERS & MARKET TRENDS

Global Menace of Coronary Artery Disease (CAD) – A Major Growth Driver

Table 1. Global Annual Medical Cost of CVD in the United States: 2015-2030 (includes corresponding Graph/Chart)

Table 2. Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)

Table 3. Top 10 Causes of Death Globally: 2015 (includes corresponding Graph/Chart)

Table 4. Top 10 Causes of Death in Low-Income Economies: 2015 (includes corresponding Graph/Chart)

Table 5. Top 10 Causes of Death in Lower-Middle-Income Economies: 2015 (includes corresponding Graph/Chart)

Table 6. Top 10 Causes of Death in Upper-Middle-Income Economies: 2015 (includes corresponding Graph/Chart)

Table 7. Top 10 Causes of Death in High-Income Economies: 2015 (includes corresponding Graph/Chart)

Ageing Demographics and Longer Life Expectancy Bolsters Market Growth

Table 8. Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)

Table 9. Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)

Rising Middle Class Population Aids Growth

Table 10. Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P (includes corresponding Graph/Chart)

Rising Healthcare Expenditure: Opportunities in Store

Table 11. Top Countries with the Highest Per Capita Healthcare Spending (2014)
(includes corresponding Graph/Chart)

Table 12. Healthcare Spending as % of GDP by Geographic Region: 2016 (includes
corresponding Graph/Chart)

Risk of CAD in Obesity Offers Prospects for Coronary Stenting

Table 13. Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely
Obese Adults for 2014 & 2025 (includes corresponding Graph/Chart)

Table 14. Severely Obese Population (in Thousands) Worldwide by Country: 2014 &
2025 (includes corresponding Graph/Chart)

Diabetics at Higher Risk of Heart Diseases

Table 15. Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years)
with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)

Table 16. Global Prevalence (%) of Diabetes in Adults (20-79) by Region: 2015 & 2040
(includes corresponding Graph/Chart)

Table 17. Global Prevalence of Diabetes by Gender (2015 & 2040): Number of Adults
Diagnosed with Diabetes (in Million) for Men and Women (includes corresponding
Graph/Chart)

Table 18. Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in
Million) for 2015 & 2040 (includes corresponding Graph/Chart)

The Hypertension-Cholesterol Link to Drive Demand

Table 19. Worldwide Prevalence of Hypertension (BP \geq 140 OR DBP \geq 90) (age-
standardized estimate) among Male and Female (2014): Breakdown by Select
Countries

Spurt in Medical Tourism Offers Growth Opportunities
Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
Metal Stents Vis-à-vis Other Stents
Alternative Therapies/Devices: Threats to Coronary Stents
Cell Transplantation – A Threat to Coronary Stents

4. PIPELINE ANALYSIS

Falcon from Abbott
Fortitude, Aptitude, and Magnitude from Amaranth
Renuvia from Boston Scientific
Ideal from Xenogenics
MeRes from Meril
Mirage from Manli Cardiology
Xinsorb from HuaAn Biotechnology
Firesorb from MicroPort
Unity from QualiMed

5. REGULATORY FRAMEWORK

The United States
Europe
Australia

6. PRODUCT OVERVIEW

7. RECENT INDUSTRY ACTIVITY

The DGCI Warns Against the Use of Absorb in 2.5 mm or Narrower Blood Vessels
Akesys and Elixir Medical Completes Successful Implantation of PRAVA for Peripheral Vascular Disease
Elixir Medical Showcases DESolve CX and AMITY at EuroPCR 2016
Micell Technologies Announces Commercialization of MiStent SES in Europe

8. CLINICAL TRIALS AND PRODUCT APPROVALS

Elixir Medical Confirms Excellent 5-Year Clinical Data for DESolve
Amaranth Medical Announces Nine-month Follow-up RENASCENT-II Study Results of

the APTITUDE

Abbott's Absorb Receives Approval as the Japan's First Fully Dissolving Heart Stent

Amaranth Medical Initiates Clinical Study for MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold

Abbott's Absorb Receives Health Canada Approval

BIOTRONIK Obtains CE Mark Approval for Magmaris, the First Magnesium Bioresorbable Scaffold

Abbott's Absorb Receives FDA Approval

US FDA Approves Boston Scientific's SYNERGY BP-DES

Abbott Receives CE Mark for Absorb GT1

ART Receives CE Mark Clearance for its Pure Bioresorbable Scaffold

9. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)

Amaranth Medical, Inc. (USA)

Arterial Remodeling Technologies SA (France)

BIOTRONIK SE & Co. KG (Germany)

Elixir Medical Corp. (USA)

Kyoto Medical Planning Co., Ltd. (Japan)

REVA Medical, Inc. (USA)

10. GLOBAL MARKET PERSPECTIVE

Table 20. World Current and Future Analysis for Bioresorbable Scaffolds by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 21. World 9-Year Perspective for Bioresorbable Scaffolds by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2017 and 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis

Abbott's Decision to End Absorb Sales Brings the US Bioresorbable Scaffolds Market to a Standstill

Increasing Incidence of CAD to Drive the Need for More Research into Bioresorbable Stents

Rising CVD Incidence – A Major Growth Driver

Table 22. Cardiovascular Disease Incidence in the US by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart)

Table 23. Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)

Ageing Population – A Vital Demography

Table 24. Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Clinical Trials and Product Approvals

Strategic Corporate Development

Select Key Players

B. Market Analytics

Table 25. The US Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US\$ Thousands for Years 2016 through 2024

2. EUROPE

A. Market Analysis

The Largest Market for Bioresorbable Scaffolds Globally

Abbott Restricts Availability of Absorb

Growth Drivers

Cardiovascular Disease in Europe – A Perspective

Europe – A Highly Diverse Market

Absorbable Stents & the Controversies Surrounding Them

Ageing Population Boosts Demand for Biodegradable Stents

Table 26. European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart)

Strategic Corporate Developments

Product Approvals

Key Players

B. Market Analytics

Table 27. European Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US\$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC

A. Market Analysis

The Fastest Growing Market for Bioresorbable Scaffolds

Growth Drivers

Aging Populace – Potential Opportunities

Table 28. Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)

Asia-Pacific – A Price Sensitive Market

India & China Offer Significant Growth Opportunities

Table 29. China and India Lead Global Population (2015): Table Depicting China and India's Huge Population Vis-a-Vis Other Countries' Population (in Millions) by Age Group (includes corresponding Graph/Chart)

Focus on Select Markets

Australia

India

Japan

China

Strategic Corporate Development
Kyoto Medical Planning Co., Ltd. (Japan) – A Key Player
B. Market Analytics

Table 30. Asia-Pacific Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US\$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

4. REST OF WORLD

A. Market Analysis
Product Approvals
B. Market Analytics

Table 31. Rest of World Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US\$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 17 (including Divisions/Subsidiaries - 18)
The United States (6)
Japan (1)
Europe (5)
 France (1)
 Germany (2)
 The United Kingdom (1)
 Rest of Europe (1)
Asia-Pacific (Excluding Japan) (6)

I would like to order

Product name: Bioresorbable Scaffolds: Market Research Report

Product link: <https://marketpublishers.com/r/BF8B659E49BEN.html>

Price: US\$ 5,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BF8B659E49BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970